April 26th 2024
"I think in terms of the 2 large tool sets we have, biomarker testing through urine or blood tests and imaging. I think both are only going to get better," says Jeffrey Tosoian, MD, MPH.
Medical Crossfire®: Expert Exchanges to Maximize Clinical Outcomes for Patients with CRPC Through Evidence-Based Personalized Therapy
View More
How the Experts Treat NMIBC During a BCG Shortage—Integrating Recent Approvals and Investigational Therapies
View More
Staying Abreast of the Prostate Cancer Treatment Paradigm From Risk Stratification to Adaptive Sequencing Strategies
View More
Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?
View More
Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer
View More
Medical Crossfire®: How Will Emerging Data Inform Treatment Planning for Patients With Prostate Cancer in the Community?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Plant-based diet linked to greater QOL in patients with prostate cancer
February 13th 2024"Our findings offer hope for those looking for ways to improve their quality of life after undergoing surgery, radiation, and other common therapies for prostate cancer, which can cause significant [adverse] effects," says Stacy Loeb, MD, MSc.
Racial representation affects trust of online prostate cancer content
February 12th 2024"Not only does it impact trust in the information, but a lack of Black representation in prostate cancer content gave the impression that Black men are at lower risk for prostate cancer,” says Stacy Loeb, MD, MSc.
Researchers identify markers of enzalutamide resistance in prostate cancer
February 12th 2024"We hope that this study will build a roadmap to personalized therapeutic advice for patients with advanced prostate cancer and potentially will improve their quality of life and outcomes," says Antonina Mitrofanova, PhD.
Future Research and Development of Abiraterone Combination Therapies
February 9th 2024In this video, experts share their opinion on the potential for novel combination therapies involving micronized abiraterone, particularly in conjunction with PARP inhibitors like olaparib or niraparib, as evidenced in clinical trials such as PROpel and MAGNITUDE. Additionally, they highlight other potential novel combinations like abiraterone with prednisolone and enzalutamide (STAMPEDE trial), and the integration of abiraterone in treatments involving radiation and androgen deprivation therapy (ADT).
Collaborative Strategies in Urology: Enhancing Treatment Access and Education
February 9th 2024Expert urologists discuss the impact of their formulary on prescribing abiraterone for metastatic castration-resistant prostate cancer (mCRPC), emphasizing its use in special patient populations and the importance of accessibility. They highlight the role of educational support and collaboration with manufacturers in facilitating access to treatments not typically included in the formulary, especially for unique patient groups. They emphasize the importance of manufacturer collaboration, Medicare changes, and specialized programs for aiding low-income seniors, underscoring the commitment to enhancing patient access and compliance in healthcare.
Prostate cancer report card aims to improve patients’ understanding of treatment options
February 6th 2024“The more informed the patients are, the more likely they are to participate in decision making…Patient engagement in decisions reduces decisional regret and fosters patient satisfaction with treatment outcomes,” the researchers wrote.
Abiraterone Access Barriers and Practice-Level Support for Diverse Patient Populations
February 2nd 2024In this episode, experts share their perspectives from their urology practices on addressing challenges such as insurance coverage, access issues, and the frequency of prior authorization (PA) denials and subsequent appeals. Co-panelists emphasize the need for additional information required by physicians to effectively appeal PA denials. Dr De La Cerda highlights the support his urology practice provides to meet the needs of his unique patient population.
Managing Steroid-related Effects with Abiraterone Therapy
February 2nd 2024In this episode, Dr. Christopher M. Pieczonka and Dr. Jose De La Cerda discuss the nuances of prescribing abiraterone acetate related to strategies for patient counseling on prednisone and methylprednisolone use and managing steroid-related side effects, dosing adjustments in patients with liver issues, emphasizing the importance of close monitoring and individualized care in prostate cancer treatment.
Optimizing Abiraterone Therapy: Dosing, Administration, and Patient Outcomes
January 26th 2024In this episode, Dr. Christopher M. Pieczonka and Dr. Jose De La Cerda explores the differences in dosing and administration of abiraterone acetate products, including the impact of food effects, and optimizing therapy for special populations with comorbidities like diabetes, hypertension, and obesity. They share insights from their clinical experience on patient compliance, tolerability, and quality of life improvements with micronized abiraterone.
Abiraterone Formulations for mCRPC: Effectiveness, Access, and Cost Implications
January 26th 2024Dr. Christopher M. Pieczonka and Dr. Jose De La Cerda discuss the various formulations of abiraterone, including micronized and non-micronized forms in combination with prednisone or methylprednisolone, including safety and effectiveness. They share insights on the specific patient populations for whom micronized abiraterone is particularly beneficial, how patient specific needs or comorbidities influence treatment appropriateness. They also delve into the accessibility of these formulations, emphasizing the importance of proper diagnosis codes to enhance medication approval processes.
Navigating Access Among Treatment Choices for Patients with mCRPC
January 26th 2024Dr. Jose De La Cerda and Dr. Christopher M. Pieczonka shed light on their approach to prescribing medicines for patients with metastatic castration-resistant prostate cancer (mCRPC). They highlight the importance of patient access to care, discuss the availability of various therapies, including novel hormonal agents and infusions, and anticipate a positive shift in treatment accessibility in the coming years due to government initiatives.